Publicacións en colaboración con investigadores/as de Complejo Hospitalario Universitario de Albacete (18)

2021

  1. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

2019

  1. A composite indicator to assess the quality of care in the management of patients with rheumatoid arthritis in outpatient rheumatology clinics

    Reumatologia Clinica, Vol. 15, Núm. 3, pp. 156-164

2015

  1. Body mass index and doses at organs at risk in a mediterranean population treated with postoperative vaginal cuff brachytherapy

    Cancer Research and Treatment, Vol. 47, Núm. 3, pp. 473-479

  2. Dosimetric analysis of rectal filling on rectal doses during vaginal cuff brachytherapy

    Brachytherapy, Vol. 14, Núm. 4, pp. 458-463

  3. Erratum to "Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project" [Semin Arthritis Rheum 44 (2015) 618-626]

    Seminars in Arthritis and Rheumatism

  4. Red eyes presenting with a fistulous lesion in the left lower extremity: A case report

    Journal of Medical Case Reports, Vol. 9, Núm. 1

  5. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640

2014

  1. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 5, pp. 640-646

  2. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-Alpha therapy have higher TRAIL levels than controls: A potential compensatory effect

    Mediators of Inflammation, Vol. 2014

  3. Tocilizumab in refractory aortitis: A study on 16 patients and literature review

    Clinical and Experimental Rheumatology, Vol. 32, Núm. SUPPL.82

2012

  1. Infections in patients with rheumatic diseases treated with TNF antagonists

    Current Pharmaceutical Biotechnology, Vol. 13, Núm. 8, pp. 1418-1425

2011

  1. Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists

    Seminars in Arthritis and Rheumatism, Vol. 41, Núm. 1, pp. 71-80

  2. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

    Seminars in Arthritis and Rheumatism, Vol. 40, Núm. 4, pp. 330-337

  3. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

    Seminars in Arthritis and Rheumatism, Vol. 41, Núm. 3, pp. 524-533

  4. Infecciones en pacientes tratados con antagonistas del factor de necrosis tumoral: incidencia, etiología y mortalidad en el registro BIOBADASER

    Medicina Clinica, Vol. 137, Núm. 12, pp. 533-540

2010

  1. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1751-1755

  2. Power doppler ultrasonography assessment of entheses in spondyloarthropathies: Response to therapy of entheseal abnormalities

    Journal of Rheumatology, Vol. 37, Núm. 10, pp. 2110-2117

1997

  1. Lupus eritomatoso neonatal

    Anales españoles de pediatría: Publicación oficial de la Asociación Española de Pediatría ( AEP ), Vol. 47, Núm. 3, pp. 311-314